Stockholm, 26 may 2020 — Devyser welcomes Torbjörn Andersson as Chief Commercial Officer in charge of global sales and marketing of Devyser’s genetic tests. Torbjörn has extensive experience in building and leading international sales organisations and distributor networks in the life science industry. He joins us most recently from Biotage AB where he was the Head …
Unfortunately, the EFI 2020 conference has been postponed due to the current COVID-19 pandemic concerns. Another date will be communicated to us soon! Meanwhile, let us know if you have any questions about our Chimerism NGS solutions or any of our other products and we will be happy to answer you. Link to EFI’s commitee …
Today is World Cancer Day, as advocated by the Union for International Cancer Control. Their global advocacy for “Treatment For All”, includes 4 important pillars – Improved public health data, early diagnosis, timely treatment, and supportive care.
Devyser is excited to announce a new partnership with Biotecnomica in Peru! Our products have now been used to improve laboratory workflows in over 60 countries around the world!
Devyser is now searching for 2 new research scientists and a senior scientist to join our research and development team! Do you know a stellar researcher with experience in NGS, qPCR and diagnostics? This could be the role for you! Did you know that Devyser is one of Swedens best workplaces? With a diverse international …
Cancer is overtaking heart disease as the leading cause of death, according to a study published recently in The Lancet medical journal. While heart disease remains the overall leading cause globally, the study of nearly 156k participants, across 21 countries over 11 years, has identified a trend that as living conditions improve, cancer begins to …
Cancer overtaking heart disease as leading cause of death Read More »
We are very happy to announce that TÜV SÜD has verified the update of our quality management system to the latest revision – ISO13485:2016! This is the first milestone in our compliance and transition from the previous IVD Directive (IVDD) to the newly adopted IVD Regulation (IVDR).
Devyser is extremely proud to have been recognised as one of Sweden’s best workplaces (Small Organisations). Across all categories Devyser was the only nominated workplace from the biotech/medtech industry in Sweden. This is a wonderful recognition of the teamwork that our colleagues exhibit every day, thank you to all who make Devyser the wonderful workplace …
Swedish molecular diagnostics company Devyser, announced today at the 45th annual European Bone Marrow Transplantation (EBMT) meeting in Frankfurt, Germany, the release of a new NGS-based assay for ultrasensitive and precise measurement of mixed chimerism after Human Stem Cell Transplantation. At EBMT, Devyser presented data obtained with the new Devyser Chimerism assay generated in collaboration …
Devyser launches first NGS-based test for mixed chimerism Read More »
Devyser is pleased to announce the publication of a new whitepaper Familial Hypercholesterolemia: Genetic Diagnosis and Cascade Testing Using NGS. The 6th in our Expert Review series, this paper is co-authored by Peter Benedek and Kristina Duvefelt, of Karolinska University Hospital, Stockholm. The paper is a guide to conducting testing using NGS, and the benefits of …
